Evidence map›Paper›PMID 28939477›Full record

ArticleAntiviral research2017

A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.

Lukai Zhai, Julianne Peabody, Yuk-Ying Susana Pang, John Schiller, Bryce Chackerian, Ebenezer Tumban

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lukai ZhaiDepartment of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA.
Julianne PeabodyDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
Yuk-Ying Susana PangLaboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
John SchillerLaboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Bryce ChackerianDepartment of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
Ebenezer TumbanDepartment of Biological Sciences, Michigan Technological University, Houghton, MI 49931, USA. Electronic address: etumban@mtu.edu.
Michigan Technological University · USNational Institutes of Health · USUniversity of New Mexico · US

Funding

The EPI-STI Biostatistics and Bioinformatics Core (Cuzick/Wheeler)U19AI113187 · NIAID · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI WHEELER, COSETTE MARIE · 2014 to 2018
$12.6M
Development of a Multi-epitope L2 Bacteriophage VLPs Vaccine to Enhance Protection against Oral HPV Infections in HIV patientsR15DE025812 · NIDCR · MICHIGAN TECHNOLOGICAL UNIVERSITY · PI TUMBAN, EBENEZER · 2016 to 2016
$457k
NIAID NIH HHS U19 AI113187NIDCR NIH HHS R15 DE025812
6 · The paper itself

Abstract

Human papillomaviruses (HPVs) cause approximately 5% of cancer cases worldwide. Fortunately, three prophylactic vaccines have been approved to protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is predicted to offer protection against the HPV types that cause ∼90% of cervical cancer, 86% of HPV-associated penile cancers, and ∼93% of HPV-associated head & neck cancers. As an alternative to Gardasil-9, we developed and tested a novel candidate vaccine targeting conserved epitopes in the HPV minor capsid protein, L2. We displayed a tandem HPV31/16L2 peptide (amino acid 17-31) or consensus peptides from HPV L2 (amino acid 69-86 or 108-122) on the surface of bacteriophage MS2 virus-like particles (VLPs). Mice immunized with the MS2 VLPs displaying the tandem peptide or immunized with a mixture of VLPs (displaying the tandem peptide and consensus peptide 69-86) elicited high titer antibodies against individual L2 epitopes. Moreover, vaccinated mice were protected from cervicovaginal infection with HPV pseudoviruses 16, 31, 45, 58 and sera from immunized mice neutralized HPV pseudoviruses 18 and 33 at levels similar to mice immunized with Gardasil-9. These results suggest that immunization with a tandem, L2 peptide or a low valency mixture of L2 peptide-displaying VLPs can provide broad protection against multiple HPV types.

Indexed as

AnimalsAntibodies, ViralCapsid ProteinsCross ProtectionDisease Models, AnimalEpitopesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18HumansLevivirusMiceMice, Inbred BALB CNeutralization TestsPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPeptidesAntibodies, ViralCapsid ProteinsEpitopesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus VaccinesPeptidesVaccines, Virus-Like ParticleBacteriophage MS2-L2 VLPsGardasil-9HPV vaccineNeutralizationProtectionTandem L2 peptide

Identifiers

PMID28939477
PMCPMC5675787
OpenAlexW2754267804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.